新辅助化疗后即刻乳房重建与单纯乳房切除的远期肿瘤学结局比较
该回顾性倾向评分匹配研究纳入1266例接受新辅助化疗后乳房切除的患者,匹配后比较323例即刻重建(保留乳头或皮肤)与323例单纯切除。中位随访约67-68个月,两组局部复发、区域复发、远处转移及5年局部无复发生存、无病生存、无远处转移生存和总生存均无显著差异。结论提示新辅助化疗背景下即刻重建的远期肿瘤学结局与单纯切除相当。
要点
- 新辅助化疗后即刻重建(保留乳头/皮肤)与单纯切除的5年肿瘤学结局无显著差异。
- 两组局部复发率分别为3.7%与3.4%,区域复发率7.1%与5.3%,远处转移率17.3%与18.6%。
- 5年总生存率即刻重建组92.0%,单纯切除组89.3%(HR 0.847,95%CI 0.530-1.353)。
核心结论
- 新辅助化疗后行保留乳头或皮肤的即刻乳房重建,其远期肿瘤学结局与单纯乳房切除相当,提示该策略可行。
主要发现
- 中位随访即刻重建组67个月(范围17-125),单纯切除组68个月(范围17-126)。
- 5年总生存率92.0% vs 89.3%(HR 0.847,95%CI 0.530-1.353,P=0.49)。
临床怎么用
- 对于接受新辅助化疗的乳腺癌患者,可考虑在保留乳头或皮肤的乳房切除时行即刻乳房重建,远期肿瘤学安全性与本研究中单纯切除相当。
局限性
- 本研究为单中心回顾性设计,即使经倾向评分匹配,仍可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: An increasing number of patients with breast cancer receiving neoadjuvant chemotherapy (NACT) undergo immediate breast reconstruction (IBR) with nipple-sparing mastectomy (NSM) or skin-sparing mastectomy (SSM) as surgical treatment. However, the oncologic efficacy and safety of this treatment sequencing strategy is unclear. OBJECTIVE: To compare the long-term oncologic outcomes of IBR with NSM/SSM and conventional mastectomy (CM) alone for breast cancer in the NACT setting. DESIGN, SETTING, AND PARTICIPANTS: A retrospective, propensity score-matched case-control study was conducted at Asan Medical Center, Seoul, Korea. A total of 1266 patients with breast cancer who underwent NACT followed by mastectomy with or without breast reconstruction between January 1, 2010, and November 30, 2016, were included. Data analysis was performed from July 1, 2019, to January 24, 2020. After propensity score matching, 323 patients who underwent IBR with NSM/SSM and 323 who underwent CM alone were selected for comparison of long-term oncologic outcomes. MAIN OUTCOMES AND MEASURES: The 5-year local recurrence-free survival, disease-free survival, distant metastasis-free survival, and overall survival rates were calculated using the Kaplan-Meier method and compared using log-rank tests. Hazard ratios (HRs) and 95% CIs were estimated using the Cox proportional hazards regression model. RESULTS: After matching, the median follow-up periods were 67 (range, 17-125) months for the IBR group and 68 (range, 17-126) months for the CM-alone group. Median age of the women in the IBR group was 42 (range, 23-72) years; median age of those in the CM-alone group was 46 (range, 30-75) years. No significant differences were observed between the IBR and CM-alone groups in local recurrence (3.7% vs 3.4%; P = .83), regional recurrence (7.1% vs 5.3%; P = .33), or distant metastasis (17.3% vs 18.6%; P = .68) rates. There was also no significant difference between the IBR and CM-alone groups in 5-year local recurrence-free survival (95.6% vs 96.7%; HR, 1.124; 95% CI, 0.495-2.549; P = .78), disease-free survival (76.5% vs 79.9%; HR, 1.089; 95% CI, 0.790-1.500; P = .60), distant metastasis-free survival (82.5% vs 82.5%; HR, 0.941; 95% CI, 0.654-1.355; P = .74), or overall survival (92.0% vs 89.3%; HR, 0.847; 95% CI, 0.530-1.353; P = .49) rates. CONCLUSIONS AND RELEVANCE: The long-term oncologic outcomes of IBR with NSM/SSM for breast cancer in this study appeared to be comparable to those of CM alone after NACT, suggesting the feasibility of IBR with NSM/SSM in the NACT setting.
引用
- Wu ZY, Kim HJ, Lee JW, et al. Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast Cancer in the Setting of Neoadjuvant Chemotherapy. JAMA Surg. 2020. PMID: 33052412. doi:10.1001/jamasurg.2020.4132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。